Hematological Phenotype of COVID-19-Induced Coagulopathy: Far from Typical Sepsis-Induced Coagulopathy

被引:25
|
作者
Umemura, Yutaka [1 ,2 ]
Yamakawa, Kazuma [3 ]
Kiguchi, Takeyuki [1 ]
Nishida, Takeshi [1 ]
Kawada, Masahiro [1 ]
Fujimi, Satoshi [1 ]
机构
[1] Osaka Gen Med Ctr, Div Trauma & Surg Crit Care, Sumiyoshi Ku, 3-1-56 Bandai Higashi, Osaka 5588558, Japan
[2] Osaka Univ, Dept Traumatol & Acute Crit Med, Grad Sch Med, Osaka 5650871, Japan
[3] Osaka Med Coll, Dept Emergency Med, Osaka 5588558, Japan
关键词
COVID-19; sepsis; acute respiratory distress syndrome; blood coagulation disorders; biomarkers; DISSEMINATED INTRAVASCULAR COAGULATION; CRITICALLY-ILL PATIENTS; DIAGNOSTIC-CRITERIA; MULTICENTER;
D O I
10.3390/jcm9092875
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Blood coagulation disorders commonly occur with severe coronavirus disease 2019 (COVID-19). However, there is only limited evidence on differentiating the pattern of the hemostatic parameters from those of typical sepsis-induced coagulopathy (SIC). Methods: To elucidate the specific pattern of coagulopathy induced by COVID-19 pneumonia, this retrospective, observational study targeted consecutive adult patients with COVID-19-induced acute respiratory distress syndrome (ARDS) and compared hemostatic biomarkers with non-COVID-19-induced septic ARDS. Multilevel mixed-effects regression analysis was performed and Kaplan-Meier failure curves were constructed. Results: We enrolled 24 patients with COVID-19-induced ARDS and 200 patients with non-COVID-19-induced ARDS. Platelet count, antithrombin activity, and prothrombin time in the COVID-19 group were almost within normal range and time series alterations of these markers were significantly milder than the non-COVID-19 group (p= 0.052, 0.037, and 0.005, respectively). However, fibrin/fibrinogen degradation product and D-dimer were significantly higher in the COVID-19 group (p= 0.001, 0.002, respectively). COVID-19 patients had moderately high levels of thrombin-antithrombin complex and plasmin-alpha2-plasmin inhibitor complex but normal plasminogen activator inhibitor-1 level. Conclusions: The hematological phenotype of COVID-19-induced coagulopathy is quite different from that in typical SIC characterized by systemic hypercoagulation and suppressed fibrinolysis. Instead, local thrombus formation might be promoted in severe COVID-19.
引用
收藏
页码:1 / 11
页数:11
相关论文
共 50 条
  • [1] Estimating the impact of COVID-19-induced coagulopathy
    Subramaniam, Ashwin
    Alamgeer, Muhammad
    ANNALS ACADEMY OF MEDICINE SINGAPORE, 2021, 50 (04) : 294 - 296
  • [2] COVID-19-induced coagulopathy and thrombosis manifestations
    Sedlaczek, O.
    Wagner, W.
    Dempfle, C. E.
    RADIOLOGE, 2021, 61 (10): : 909 - 914
  • [3] Covid-19-induced coagulopathy and observed benefits with anticoagulation
    Karimzadeh, Sedighe
    Dong, Vinh
    Hassan, Osama Gamal
    Raut, Akshay
    Fouda, Ahmed
    Parrill, Allison
    Eaton, Kimberly
    Nguyen Tien Huy
    TRANSFUSION AND APHERESIS SCIENCE, 2020, 59 (06)
  • [4] COVID-19-induced coagulopathy : Experience, achievements, prospects
    Dubey, Leonid
    Dorosh, Olga
    Dubey, Nataliya
    Doan, Svitlana
    Kozishkurt, Olena
    Duzenko, Oleksandr
    Kozlova, Olena
    Ievtukh, Veronika
    Ladny, Jerzy R.
    Pruc, Michal
    Szarpak, Lukasz
    Pukach, Julia
    CARDIOLOGY JOURNAL, 2022,
  • [5] COVID-19-induced coagulopathy : Experience, achievements, prospects
    Dubey, Leonid
    Dorosh, Olga
    Dubey, Nataliya
    Doan, Svitlana
    Kozishkurt, Olena
    Duzenko, Oleksandr
    Kozlova, Olena
    Ievtukh, Veronika
    Ladny, Jerzy R.
    Pruc, Michal
    Szarpak, Lukasz
    Pukach, Julia
    CARDIOLOGY JOURNAL, 2023, 30 (03) : 453 - 461
  • [6] Clinical value of pediatric sepsis-induced coagulopathy score in diagnosis of sepsis-induced coagulopathy and prognosis in children
    Xiang, Long
    Ren, Hong
    Wang, Ying
    Zhang, Jian
    Qian, Juan
    Li, Biru
    An, Kang
    Fu, Lijun
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2021, 19 (12) : 2930 - 2937
  • [7] A proposal for the management of COVID-19-induced coagulopathy in adults
    Ignacio-Ibarra, Gregorio
    Teresa Garcia-Lee, Ma
    Gonzalez-Avila, Ana, I
    Garcia-Chavez, Jaime
    Guzman-Chores, Laura
    Ledesma-de la Cruz, Cindy
    Lugo-Garcia, Yolanda
    Juarez-Lara, Jessi
    Garcia-Vazquez, Mauricio
    Madera-Maldonado, Cristina E.
    Ramos-Penafiel, Christian O.
    Majluf-Cruz, Abraham
    GACETA MEDICA DE MEXICO, 2021, 157 (02): : 209 - 214
  • [8] Sepsis-induced coagulopathy (SIC) in the management of sepsis
    Ji, Yun
    ANNALS OF INTENSIVE CARE, 2025, 15 (01):
  • [9] Sepsis-induced coagulopathy (SIC) in the management of sepsis
    Iba, Toshiaki
    Helms, Julie
    Levy, Jerrold H.
    ANNALS OF INTENSIVE CARE, 2024, 14 (01):
  • [10] Can Ticagrelor be used to prevent sepsis-induced coagulopathy in COVID-19?
    Omarjee, Loukman
    Meilhac, Olivier
    Perrot, Frederique
    Janin, Anne
    Mahe, Guillaume
    CLINICAL IMMUNOLOGY, 2020, 216